TD Waterhouse Canada’s Axsome Therapeutics AXSM Stock Holding History

TD Waterhouse Canada’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$48.1K	Hold	200	–	–	﹤0.01%	1426
2026 Q1	$34.4K	Buy	+200	New	+$34.5K	﹤0.01%	1461

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TD Waterhouse Canada's AXSM Position: Q2 2026 in Review

TD Waterhouse Canada held its Axsome Therapeutics (AXSM) position steady in Q2 2026 at 200 shares worth $48.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1426.

TD Waterhouse Canada first reported a position in AXSM in Q1 2026 and has held it in 2 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

TD Waterhouse Canada held 200 shares of Axsome Therapeutics worth $48.1K as of Q2 2026.
TD Waterhouse Canada left its Axsome Therapeutics share count unchanged in Q2 2026.
Axsome Therapeutics made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #1426 holding.
TD Waterhouse Canada first reported a position in Axsome Therapeutics in Q1 2026 and has held it in 2 quarters since.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.